Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX versus CEFPODOXIME PROXETIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX versus CEFPODOXIME PROXETIL.
CEFIZOX vs CEFPODOXIME PROXETIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefizox (ceftizoxime) is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition.
Cefpodoxime proxetil is a prodrug that is de-esterified in vivo to cefpodoxime, a third-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and disrupting peptidoglycan cross-linking, leading to cell lysis. It has broad-spectrum activity against Gram-positive and Gram-negative bacteria.
1-2 g IV/IM every 8-12 hours; maximum 12 g/day for severe infections.
200 mg orally every 12 hours
None Documented
None Documented
1.7-1.9 hours in adults; prolonged to 15-25 hours in severe renal impairment (CrCl <10 mL/min)
Terminal elimination half-life of cefpodoxime is 2.2-2.8 hours in healthy adults; prolonged to 5.9-9.8 hours in moderate renal impairment (CrCl 10-30 mL/min) and up to 13-14 hours in severe impairment (CrCl <10 mL/min).
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); biliary (<1%); fecal (minimal)
Renal excretion of unchanged drug (29-33%) and fecal/biliary elimination of inactive metabolites; 80% of radiolabeled dose recovered in urine and feces over 8 days.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic